U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
180361180361Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary SiteCompletedHas ResultsNeoplasms, Unknown PrimaryDrug: Oxaliplatin|Drug: Capecitabinehttps://ClinicalTrials.gov/show/NCT00193609
180362180362Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary SiteCompletedHas ResultsNeoplasms, Unknown PrimaryDrug: Etoposide|Drug: Gemcitabine|Drug: Irinotecan|Drug: Paclitaxel|Drug: Carboplatinhttps://ClinicalTrials.gov/show/NCT00193596
180363180363Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid TumorsCompletedNo Results AvailableCancerDrug: Topotecan|Drug: Carboplatinhttps://ClinicalTrials.gov/show/NCT00193583
180364180364Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid TumorsCompletedNo Results AvailableCancerDrug: Topotecan|Drug: Docetaxelhttps://ClinicalTrials.gov/show/NCT00193570
180365180365Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple MyelomaCompletedNo Results AvailableMultiple MyelomaDrug: Bortezomibhttps://ClinicalTrials.gov/show/NCT00193557
180366180366Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple MyelomaCompletedNo Results AvailableMultiple MyelomaDrug: Arsenic Trioxide|Drug: Thalidomidehttps://ClinicalTrials.gov/show/NCT00193544
180367180367Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine CarcinomaCompletedNo Results AvailableNeuroendocrine CarcinomaDrug: Paclitaxel|Drug: Carboplatin|Drug: Etoposidehttps://ClinicalTrials.gov/show/NCT00193531
180368180368Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNo Results AvailableChronic Lymphocytic Leukemia|Small Lymphocytic LymphomaDrug: Arsenic Trioxidehttps://ClinicalTrials.gov/show/NCT00193518
180369180369Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell LymphomaCompletedNo Results AvailableNon-Hodgkins LymphomaDrug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide|Drug: Rituximab|Drug: 90Y Zevalinhttps://ClinicalTrials.gov/show/NCT00193505
180370180370A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's LymphomaCompletedHas ResultsLymphoma, FollicularDrug: Bevacizumab|Drug: Rituximabhttps://ClinicalTrials.gov/show/NCT00193492
180371180371Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's LymphomaCompletedHas ResultsNon-Hodgkins LymphomaDrug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Vincristine|Drug: Prednisone|Drug: Rituximabhttps://ClinicalTrials.gov/show/NCT00193479
180372180372Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNo Results AvailableNon-Hodgkins LymphomaDrug: Rituximab|Drug: Fludarabine|Drug: CAMPTH-1Hhttps://ClinicalTrials.gov/show/NCT00193466
180373180373Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung CancerCompletedHas ResultsLung CancerDrug: Gemcitabine|Drug: Docetaxel|Drug: Cetuximabhttps://ClinicalTrials.gov/show/NCT00193453
180374180374Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's LymphomaCompletedNo Results AvailableNon-Hodgkins LymphomaDrug: Rituximab|Drug: CHOP|Drug: CVP|Drug: Ibritumomab Tiuxetanhttps://ClinicalTrials.gov/show/NCT00193440
180375180375Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung CancerCompletedHas ResultsLung CancerDrug: Docetaxel|Drug: Gemcitabine|Drug: Carboplatin|Radiation: Radiationhttps://ClinicalTrials.gov/show/NCT00193427
180376180376Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung CancerCompletedHas ResultsLung CancerDrug: Pemetrexed|Drug: Gemcitabinehttps://ClinicalTrials.gov/show/NCT00193414
180377180377Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung CancerCompletedNo Results AvailableLung CancerDrug: Topotecanhttps://ClinicalTrials.gov/show/NCT00193401
180378180378Weekly Topotecan in the Second-Line Treatment of Small Cell Lung CancerCompletedNo Results AvailableLung CancerDrug: Topotecanhttps://ClinicalTrials.gov/show/NCT00193388
180379180379Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung CancerCompletedHas ResultsLung CancerDrug: Irinotecan|Drug: Carboplatin|Drug: Bevacizumab|Radiation: Radiationhttps://ClinicalTrials.gov/show/NCT00193375
180380180380Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung CancerCompletedNo Results AvailableLung CancerDrug: Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine|Drug: Vinorelbinehttps://ClinicalTrials.gov/show/NCT00193362
180381180381Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung CancerCompletedNo Results AvailableLung CancerDrug: Imatinib|Drug: Irinotecan|Drug: Carboplatinhttps://ClinicalTrials.gov/show/NCT00193349
180382180382Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung CancerCompletedNo Results AvailableLung CancerDrug: ZD1839https://ClinicalTrials.gov/show/NCT00193336
180383180383Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly PatientsCompletedNo Results AvailableLung CancerDrug: Docetaxel|Drug: Gemcitabinehttps://ClinicalTrials.gov/show/NCT00193323
180384180384Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung CancerCompletedNo Results AvailableLung CancerDrug: Paclitaxel|Drug: Carboplatinhttps://ClinicalTrials.gov/show/NCT00193310
180385180385Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNo Results AvailableOvary CancerDrug: Topotecan|Drug: Paclitaxel|Drug: Carboplatinhttps://ClinicalTrials.gov/show/NCT00193297
180386180386Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck CancerCompletedNo Results AvailableHead and Neck CancerDrug: Gefitinib|Drug: Docetaxel|Drug: Carboplatin|Drug: Fluorouracilhttps://ClinicalTrials.gov/show/NCT00193284
180387180387Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate CancerCompletedNo Results AvailableProstate CancerDrug: Docetaxel|Drug: Estramustinehttps://ClinicalTrials.gov/show/NCT00193271
180388180388Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell CarcinomaCompletedHas ResultsClear Cell Renal Cell CarcinomaDrug: Bevacizumab|Drug: Erlotinib|Drug: Imatinibhttps://ClinicalTrials.gov/show/NCT00193258
180389180389Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung CancerCompletedNo Results AvailableLung CancerDrug: Topotecan|Drug: Docetaxelhttps://ClinicalTrials.gov/show/NCT00193245
180390180390Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate CancerCompletedNo Results AvailableProstate CancerDrug: Docetaxel|Drug: Bortezomibhttps://ClinicalTrials.gov/show/NCT00193232

* Görseller ve İçerik tekif hakkına sahip olabilir